Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $12.9 million.

  • Exagen's Total Current Liabilities rose 4686.11% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 4686.11%. This contributed to the annual value of $13.5 million for FY2024, which is 1347.67% up from last year.
  • According to the latest figures from Q3 2025, Exagen's Total Current Liabilities is $12.9 million, which was up 4686.11% from $10.3 million recorded in Q2 2025.
  • Exagen's Total Current Liabilities' 5-year high stood at $14.0 million during Q1 2025, with a 5-year trough of $7.9 million in Q1 2021.
  • Over the past 5 years, Exagen's median Total Current Liabilities value was $9.6 million (recorded in 2022), while the average stood at $10.2 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 2201.28% in 2023, then soared by 5934.19% in 2025.
  • Quarter analysis of 5 years shows Exagen's Total Current Liabilities stood at $9.3 million in 2021, then increased by 3.27% to $9.6 million in 2022, then grew by 23.68% to $11.9 million in 2023, then increased by 13.48% to $13.5 million in 2024, then dropped by 4.56% to $12.9 million in 2025.
  • Its last three reported values are $12.9 million in Q3 2025, $10.3 million for Q2 2025, and $14.0 million during Q1 2025.